<DOC>
	<DOCNO>NCT00343525</DOCNO>
	<brief_summary>The purpose study determine safety tolerability bavituximab administer via arm vein multiple infusion examine bavituximab behaves body effect amount hepatitis C virus immune modulators individual chronic infection .</brief_summary>
	<brief_title>Repeat-Dose Study Bavituximab Patients With Chronic Hepatitis C</brief_title>
	<detailed_description>Hepatitis C virus ( HCV ) infection world wide public health concern common chronic bloodborne infection United States lead indication liver transplantation . Laboratory animal study demonstrate bavituximab bind virus virally infected cell prolongs survival lethally infect animal . This study examine safety tolerability bavituximab administer multiple infusion patient chronic HCV infection . Groups patient treat escalate dos bavituximab twice weekly 2 week follow 12 week .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>At least 18 year age Chronic Hepatitis C infection base history detectable serum HCV RNA include treatment na√Øve subject well subject partial responder and/or relapsers prior therapy ( y ) All genotype HCV acceptable Complete Blood Counts within normal limit Normal renal function ( serum creatinine within normal limit ) Normal coagulation profile ( PT/INR aPTT within normal limit ) Patients reproductive potential must agree use approved form barrier contraception . Female patient must negative serum pregnancy test prestudy ( applicable patient bilateral oophorectomy and/or hysterectomy patient postmenopausal ) Prior exposure chimeric antibody Any cause liver disease chronic hepatitis C , autoimmune alcoholic liver disease . Decompensated clinical liver disease , include history prolong clot time , hypoalbuminemia , encephalopathy , treatment elevate ammonia level , ascites Any evidence clinically significant bleeding define gross hematuria , hemoptysis , gastrointestinal bleeding Known history bleed diathesis coagulopathy ( e.g. , von Willebrand Disease Hemophilia ) Any history thromboembolic event [ e.g. , deep vein thrombosis ( DVT ) pulmonary thromboembolism ( PE ) ] include central venous catheterrelated thrombosis within past 12 month Concurrent therapy oral parenteral anticoagulant Concurrent hormone therapy ( i.e. , estrogen contraceptive , hormone replacement , antiestrogen ) Antiviral therapy within 4 week day 0 Investigational therapy within 4 week day 0 Major surgery within 4 week day 0 Pregnant nursing woman Uncontrolled intercurrent disease ( e.g. , diabetes , hypertension , thyroid disease ) Any history angina pectoris , coronary artery disease cerebrovascular accident , transient ischemic attack A history condition require antiplatelet therapy exception general cardiovascular prophylaxis aspirin A history condition require treatment ( past current ) coumarintype agent Cardiac arrhythmia require medical therapy Serious nonhealing wound ( include wound heal secondary intention , ulcer , bone fracture ) Requirement chronic daily treatment NSAIDs , antiplatelet drug ( e.g. , phosphodiesterase inhibitor , adenosine diphosphate receptor antagonist ) , steroids Cancer , autoimmune disease disease concurrent therapy know cause significant alteration immunologic function Known chronic infection HIV HBV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>HCV</keyword>
	<keyword>monoclonal antibody</keyword>
	<keyword>phase 1</keyword>
</DOC>